Inicio / Farmacia hospitalaria / Abstracts de farmacia hospitalaria / Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma

Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma

0 / 5 (0 votos)
Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma

Journal of Pharmacy & Pharmacology
First published: 

DOI: 
10.1111/jphp.12798

Jessica Cusato, Silvia De Francia, Sarah Allegra, Simona Carrella, Elisa Pirro, Francesca Maria Piccione, Francesca De Martino, Anna Ferrero, Fulvia Claudia Daffara, Massimo Terzolo, Alfredo Berruti, Francesco Di Carlo, Marco Tampellini, Antonio D’Avolio

Objectives: Mitotane is the reference drug for the adrenocortical carcinoma treatment; its pharmacological activity seems to depend on drug transformation in two active metabolites: o,p’-DDE (dichlorodiphenylethene) and o,p’-DDA (dichlorodiphenylacetate). Mitotane and metabolites are lipophilic agents; thus, they tend to accumulate into adipose tissues (white and brown), which change their prevalence seasonally. Aim of the work was to evaluate mitotane and metabolites plasma levels variation over the year, in adrenocortical cancer patients treated with Lysodren®for at least 6 months.

 

Seguir leyendo

 

Comentarios

Para dejar un comentario antes debes iniciar sesión:

¿No tienes una cuenta?

Regístrate a través de éste enlace.